Compare APWC & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APWC | IMMP |
|---|---|---|
| Founded | 1996 | 1987 |
| Country | Taiwan | Australia |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.1M | 58.2M |
| IPO Year | 1997 | 2012 |
| Metric | APWC | IMMP |
|---|---|---|
| Price | $1.38 | $0.57 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 5.6K | ★ 23.8M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.27 | $0.29 |
| 52 Week High | $2.34 | $3.53 |
| Indicator | APWC | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 49.18 | 37.95 |
| Support Level | $1.27 | $0.29 |
| Resistance Level | $1.47 | $1.81 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 63.45 | 36.65 |
Asia Pacific Wire & Cable Corp Ltd is a holding company. It is principally engaged in the manufacture and distribution of enameled wire, power cable, and telecommunications products in Thailand, Singapore, Australia, PRC, Hong Kong and certain other markets in the Asia Pacific region. It also provides project engineering services in the supply, delivery and installation of power cables (SDI). Some of the company's products are Bare wires, Power cables, Communication cables, Electronic wires & cables, and Enamelled wires. The company's geographical segments are North Asia, Thailand, and Rest of the World.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.